Dosimetric correlates for acute esophagitis in patients treated with radiotherapy for lung carcinoma

International Journal of Radiation Oncology Biology Physics

Volumn 58, Issue 4, 2004, Pages 1106-1113

  Bradley, Jeffrey ^a,c   Deasy, Joseph O ^a   Bentzen, Soeren ^b   El Naqa, Issam ^a  

^a Washington University in St Louis School of Medicine   (United States)

^b Group for Biostatistics in Oncology   (United Kingdom)

^c WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Acute esophagitis; Chemoradiotherapy; Radiotherapy

Indexed keywords

CHEMOTHERAPY; IRRADIATION; PATIENT TREATMENT; STATISTICAL METHODS; TUMORS;

THRESHOLD DOSE;

DOSIMETRY;

CARBOPLATIN; CISPLATIN; DOCETAXEL; ETOPOSIDE; GEMCITABINE; NAVELBINE; PACLITAXEL; VINBLASTINE SULFATE;

ACUTE DISEASE; ADULT; AGE; AGED; ANALYTIC METHOD; ARTICLE; CANCER CHEMOTHERAPY; CANCER PATIENT; CANCER RADIOTHERAPY; CONTROLLED STUDY; CORRELATION ANALYSIS; CRICOID; DEATH; DISEASE COURSE; DISEASE SEVERITY; DOSIMETRY; ESOPHAGITIS; FEMALE; HUMAN; INCIDENCE; LOGISTIC REGRESSION ANALYSIS; LOWER ESOPHAGUS SPHINCTER; LUNG CARCINOMA; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; MEDICAL INFORMATION; PARAMETER; PREDICTION; PRIORITY JOURNAL; RADIATION DOSE; REGRESSION ANALYSIS; SCORING SYSTEM; STATISTICAL SIGNIFICANCE; SURFACE PROPERTY; TREATMENT PLANNING; VOLUMETRY;

ACUTE DISEASE; ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; CARCINOMA, NON-SMALL-CELL LUNG; ESOPHAGITIS; FEMALE; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; RADIATION INJURIES; REGRESSION ANALYSIS; STATISTICS, NONPARAMETRIC;

EID: 1542376214     PISSN: 03603016     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijrobp.2003.09.080     Document Type: Article

References (15)

1. Jeremic B., Shibamoto Y., Acimovic L., et al. Randomized trial for hyperfractionated radiation therapy with or without concurrent chemotherapy for Stage III non-small lung cancer. J Clin Oncol. 13:1995;452-458.
2. Furuse K., Fukuoka M., Kawahara M., et al. Phase III study of concurrent versus sequential thoracic radiotherapy in combination with mitomycin, vindesine, and cisplatin in unresectable stage III non-small-cell lung cancer. J Clin Oncol. 17:1999;2692-2699.
3. Curran W.J., Scott C., Langer C., et al. Phase III comparison of sequential vs concurrent chemoradiation for patients with unresected stage III non-small cell lung cancer (NSCLC) Initial report of Radiation Therapy Oncology Group (RTOG) 9410 [Abstract]. Proc Am Soc Clin Oncol. 19:2000;1891a.
4. Byhardt R.W., Scott C., Sause W.T., et al. Response, toxicity, failure patterns, and survival in five Radiation Therapy Oncology Group (RTOG) trials os sequential and/or concurrent chemotherapy and radiotherapy for locally advanced non-small-cell carcinoma of the lung. Int J Radiat Oncol Biol Phys. 42:1998;469-478.
5. Antonadou D., Coliarakis N., Synodinou M., et al. Randomized phase III trial of radiation treatment ± amifostine in patients with advanced-stage lung cancer. Int J Radiat Oncol Biol Phys. 51:2001;915-922.
6. Maguire P.D., Sibley G.S., Zhou S. Clinical and dosimetric predictors of radiation-induced esophageal toxicity. Int J Radiat Oncol Biol Phys. 45:1999;97-103.
7. Werner-Wasik M., Pequignot E., Leeper D. Predictors of severe esophagitis include use of concurrent chemotherapy, but not the length of the irradiated esophagus A multivariate analysis of patients with lung cancer treated with nonoperative therapy. Int J Radiat Oncol Biol Phys. 48:2000;689-696.
8. Singh A.K., Lockett M.A., Bradley J.D. Analysis of clinical and dosimetric predictors of radiation-induced esophageal toxicity in patients with non-small-cell lung cancer treated with three-dimensional conformal radiation therapy. Int J Radiat Oncol Biol Phys. 55:2003;337-341.
9. Rosenman J., Halle J. High-dose conformal radiotherapy for treatment of stage IIIA/B non-small cell lung cancer Technical issues and results of a phase I/II trial. Int J Radiat Oncol Biol Phys. 54:2002;348-356.
10. Bradley J.D., Ieumwananonthachai N., Purdy J.A., et al. Gross tumor volume, critical prognostic factor in patients treated with three-dimensional conformal radiation therapy for non-small cell lung carcinoma. Int J Radiat Oncol Biol Phys. 52:2002;49-57.
11. Deasy J., Blanco A. CERR A computational environment for radiotherapy research. Med Phys. 30:2003;979-985.
12. Emami B., Lyman J., Brown A., et al. Tolerance of normal tissue to therapeutic irradiation. Int J Radiat Oncol Biol Phys. 21:1991;109-122.
13. Dillman R.O., Seagren S.L., Propert K.J., et al. A randomized trial of induction chemotherapy plus high-dose radiation versus radiation alone in Stage III non-small cell lung cancer. N Engl J Med. 323:1990;940-945.
14. Dillman R.O., Herndon J., Seagren S.L., et al. Improved survival in stage III non-small-cell lung cancer Seven year follow-up of Cancer and Leukemia Group B (CALGB) 8433 trial. J Natl Cancer Inst. 88:1996;1210-1215.
15. Sause W., Kolesar P., Taylor S., et al. Radiation Therapy Oncology Group, Eastern Cooperative Oncology Group, and Southwest Oncology Group. Final results of phase III trial in regionally advanced unresectable non-small cell lung cancer. Chest. 117:2000;358-364.